Adverse events of interest in patients with axSpA receiving JAKi include infections (especially herpes zoster); venous thromboembolism; and specific laboratory abnormalities, such as elevated CPK or lipid parameters [25]. Here, PIK3C2A is linked to venous thromboembolism.